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SHORT COMMUNICATION
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ABSTRACT
The UDP-glucose pyrophosphorylase of Streptococcus pneumoniae (GalUSpn) is absolutely required for the
biosynthesis of capsular polysaccharide, the sine qua non virulence factor of pneumococcus. Since the
eukaryotic enzymes are completely unrelated to their prokaryotic counterparts, we propose that the GalU
enzyme is a critical target to fight the pneumococcal disease. A recombinant GalUSpn was overexpressed
and purified. An enzymatic assay that is rapid, sensitive and easy to perform was developed. This assay
was appropriate for screening chemical libraries for searching GalU inhibitors. This work represents a fun-
damental step in the exploration of novel antipneumococcal drugs.
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Introduction
Streptococcus pneumoniae (the pneumococcus) is the main cause
of community-acquired pneumonia and also produces meningitis,
bacteremia and otitis media. Many different virulence factors have
been described in S. pneumoniae1,2, but the capsular polysacchar-
ide is only absolutely required for virulence in vivo3,4. To date, at
least 94 different pneumococcal capsular types have been
described5–9. This remarkable phenotypic variability appears to be
present also at the genetic level10.
The galU gene encodes a uridine diphosphate glucose pyro-
phosphorylase (UDPG:PP; UTP:glucose 1-phosphate uridylyltransfer-
ase; EC 2.7.7.9; GalU). The enzyme UDPG:PP catalyzes the
reversible formation of uridine diphosphate glucose (UDP-Glc) and
inorganic pyrophosphate (PPi) from uridine 3-phosphate (UTP) and
glucose-1-phosphate (Glc-lP).
Early studies showed that UDP-Glc is a key component in the
biosynthetic pathway of pneumococcal capsular polysaccharides
containing glucose, galactose and/or UDP-glucuronic or UDP-gal-
acturonic acids11. At least one of these sugars is a component of
every capsular polysaccharide of S. pneumoniae12.
Although it has been reported that the pneumococcal galU
gene is highly polymorphic, there is striking sequence conserva-
tion among bacterial GalU enzymes13. In addition, knockout galU
mutants of type 1 and type 3 pneumococci are unable to synthe-
size a detectable capsular polysaccharide and, consequently, are
highly attenuated in vivo14,15. Southern blot hybridization experi-
ments using DNAs prepared from pneumococcal isolates belong-
ing to different types showed that every strain tested contained a
galU homolog16.
Since GalU is required for the synthesis of UDP-Glc, the main
glucosyl donor in lipopolysaccharide and capsule biosynthesis, a
relevant role of this enzyme in virulence has also been recognized
in many other bacteria such as Klebsiella17,18, Erwinia19,
Pseudomonas20,21, Xanthomonas22, Escherichia coli O157:H719,23,
Francisella24, Proteus25, Shigella26,27, Vibrio cholerae28,
Actinobacillus29,30, Aeromonas31 or Haemophilus influenzae32.
Eukaryotic UDPG:PPs are completely unrelated to their bacterial
counterparts, suggesting the possibility that inhibitors of the bac-
terial enzymes would not be harmful to the host33.
Previously, the galU gene of S. pneumoniae (designated as
galUSpn hereafter) was cloned and expressed in Escherichia coli,
and subsequently, the purified enzyme was biochemically charac-
terized16,34. The galU gene was expressed mainly in the exponen-
tial phase of growth35.
We describe here the cloning and overexpression of the
GalUSpn enzyme and the development of a method to screen for
inhibitors in small volumes with high sensitivity.
Materials and methods
Construction of the recombinant plasmid pETgalU
Escherichia coli strains XL1 Blue and BL21 (DE3) were used for
cloning and expression, respectively. Escherichia coli strains were
grown in Luria Bertani medium (LB) (Difco; Becton Dickinson and
Company, Baltimore, MD). The complete galUSpn gene was PCR
amplified from the pMMG2 plasmid16 using oligonucleotides
pet28galUF2: 50-AGGGCTAGCATGACATCAAAAGTTAG-30 and
pet28galUR: 50-TTAGGATCCGTAGTCTTGTTCGTAGG-30. Restriction
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endonuclease sites were introduced in the primer sequences
(these are shown underlined). PCR products were purifie after
digestion with BamHI and NheI restriction enzymes from agarose
gels and ligated to the expression vector pET28a previously
digested with the same enzymes. Sequencing was performed to
verify the recombinant plasmid (pETgalU) carrying the galUSpn
gene preceded by a DNA sequence encoding for six His residues.
Expression and purification of the recombinant His6GalUSpn
Escherichia coli BL21 (DE3) was transformed with pETgalU plasmid
and grown in LB medium. The culture was incubated with shaking
(200 rpm) at 37 C in an air:medium ratio of 4:1 until the optical
density at 600 nm (OD600) reached 0.6–0.7. Then, isopropyl-b-D-thi-
ogalactopyranoside (IPTG) was added. The optimal expression con-
ditions were determined by varying the incubation temperature
and IPTG concentration (from 0.1 to 0.4mM). The maximum
amount of recombinant GalU was achieved after induction with
0.1mM IPTG followed by overnight incubation at 28 C. The
expression of GalU was assessed by analysis of total cell protein
by SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
His6GalUSpn was purified using immobilized metal affinity chro-
matography (IMAC). Briefly, cells were harvested by centrifugation,
resuspended 1:10 in buffer A (50mM Tris-HCl, 0.25 M NaCl; pH 8.0)
and disrupted by sonication (Sonics and Materials Inc., CT). After
disruption, the crude extract was clarified by centrifugation
(15 000  g for 15min) and filtered through a 0.22 lm nitrocellu-
lose membrane. The sample was conditioned in buffer A by pass-
ing through a PD-10 column (GE Healthcare, Little Chalfont, UK). A
nickel affinity column (GE HP HisTrap column), (1.0-ml bed vol-
ume) equilibrated with the same buffer was loaded with the sam-
ple. Following a washing step with buffer A containing 100mM
imidazole, step elution was performed by increasing the imidazole
concentration up to 500mM. Linear flow rate was 0.4 cm min1.
Protein separation was monitored by absorbance at 280 nm and 2-
ml fractions were collected.
Fractions containing the His6GalUSpn were immediately condi-
tioned using a PD-10 desalting column (GE Healthcare) and stored
at 20 C with 20% of glycerol. The purified protein was analyzed
by SDS-PAGE in 15% polyacrylamide gels and protein concentra-
tion was measured by the Lowry assay using bovine serum albu-
min as standard.
Enzyme activity assays
Determination of UDP-Glc:PP activity was performed using two dif-
ferent assays:
a. Standard method: the production of UDP-Glc and PPi was
monitored by a reaction coupled to the reduction of NAD,
determined by spectrophotometric measurement of NADH
formation34,36.
b. Screening method for inhibitors assay: the enzymatic activity
was evaluated in the direction of UDP-Glc synthesis by a
modification of the colorimetric method as previously
described by Fusari37. Briefly, the production of Pi, after
hydrolysis of PPi by inorganic pyrophosphatase was
quantified by the formation of a phosphomolybdate–mala-
chite green complex. The assay was performed at 37 C in a
50ll-reaction mixture containing (unless otherwise specified)
40mM morpholinepropanesulfonic acid (MOPS)-NaOH buffer
(pH 8.0), 5mM MgCl2, 7.5mM UTP, 0.16mg ml
1 BSA, 0.5U/ml
inorganic pyrophosphatase and purified His6GalUSpn. The
reaction was initiated by adding Glc-1P (7.5mM, final concen-
tration). After incubation at 37 C for 10min, the enzyme reac-
tion was terminated by adding 50 ll of malachite green
reagent (0.03% malachite green, ammonium molybdate and
0.05% Triton X-100 in 0.7 N HCl). The complex formed with
the released Pi was measured at 650 nm with a Synergy HT
Multi-Mode Microplate Reader (Biotek) detector. One unit (U)
of enzyme activity is defined as the amount of enzyme cata-
lyzing the formation of 1mol of PPi per minute (which ren-
ders 2mol of Pi after hydrolysis), under the conditions
described previously. Controls were done to correct the inter-
ference by substrates and buffer components. A standard
curve obtained by addition of various amounts of PPi
(0.13–13 nmol) and 0.04U of pyrophosphatase, was used to
determine the quantity of Pi produced.
For inhibition assays, His6GalUSpn was preincubated 30min at
37 C with 7.5mM of the following nucleoside analogs: abacavir,
decitabine stavudine and zidovudine provided by Dosa SA
(Argentina), capecitabine provided by Tuteur (Argentina) and
didanosine provided by Filaxis SA (Argentina). Then, the assay was
continued as described previously. All the chemicals used in the
enzymatic assay were purchased from Sigma-Aldrich (St. Louis).
Methanol was of chromatographic pure grade and water was Milli-
Q grade. €AKTA Purifier, His Spin Trap and PD-10 desalting columns
were purchased from GE Healthcare.
Results and discussion
The GalU UDPG:PP from S. pneumoniae is a key enzyme in the bio-
synthesis of the capsular polysaccharide of this microorganism. In
this study, galUSpn was cloned and soluble overexpressed in E. coli
Table 1. Purification of UDP-Glc pyrophosphorylase.
Product Volume (ml) Amount of protein (mg) Total activity (U) Specific activity (U/mg) Yield (%) Purification (fold)
Crude extract 10 66 23.8 107 3.6 106 1
GalU 1 8.8 4.4 107 5.05 106 18.69 1.40
Enzymatic activity was assayed using the standard method described in “Materials and methods” section.
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Figure 1. Percentage of inhibition activity of GalU with different nucleosides
analogs.
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BLE21 (DE3). Clarified bacterial protein extract was used for purifi-
cation of the recombinant protein by IMAC. The purified enzyme
displayed one band as judged by SDS-PAGE and Coomassie Blue
staining (not shown). The apparent molecular mass was consistent
with the theoretical value of the recombinant protein. On average,
1 l of culture yielded ca. 97mg of His6GalUSpn (specific activity
¼ 5.05 106 U mg1) (Table 1). The pure enzyme was stable for at
least 6 months when stored at 20 C in 20% glycerol. The colori-
metric method described in this study was optimized for UDPG:PP
activity assay in microscale grade, and rendered concordant results
to the standard method34,36.
Considering the similarity in chemical structure of natural
nucleotides and nucleosides to the nucleoside analogs, we specu-
late that these compounds could also inhibit GalU activity and
could be a useful tool to evaluate the colorimetric assay for
screening small molecule libraries and identify potential inhibitors
of GalU protein. In fact, this assay could detect GalU inhibition
activity after 30min of preincubation with the putative inhibitor at
7.5mM (Figure 1).
As it was reviewed by Berbıs et al.33, in all UDPG:PPs described
so far the interactions established with the nucleotide moiety of
the substrate are essentially the same. In the first step, UTP is
buried inside the active site pocket where it forms hydrogen
bonds with certain residues of the enzyme, while the phosphate
group remains fully accessible to the solvent. This initial binding
induces local conformational changes near the active site prior to
the subsequent steps of the reaction. We speculate that the inhibi-
tors used herein (Figure 2) could accommodate in the cleft in a
similar way as the natural substrate irrespectively of their capacity
to form hydrogen bonds.
Promiscuity towards other dNTPs has been documented for
UDPG:PPs from different sources33. The different nucleoside ana-
logs used in this study inhibit S. pneumoniae UDP-glucose pyro-
phosphorylase, including compounds containing a purine base in
their structure such as abacavir and didanosine, or even a triazine
derivative such as decitabine.
Conclusions
This study describes the successful preparation of recombinant
GalU from S. pneumoniae. It has been shown that inactivation of
the galU gene completely abolishes the formation of the capsule,
and, therefore, renders the pneumococcus completely avirulent16.
The colorimetric test in a 96-well plate proposed herein as appro-
priate to screen and characterize specific inhibitors of GalU
enzyme is a useful tool to be applied in the search of antipneumo-
coccal drugs.
Furthermore, this work represents a fundamental step in the
search of novel antipneumococcal drugs.
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